R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn et al., Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, issue.15, pp.4429-4463, 2007.

E. A. Rakha, M. E. El-sayed, A. R. Green, A. H. Lee, J. F. Robertson et al., Prognostic markers in triple-negative breast cancer, Cancer, vol.109, issue.1, pp.25-32, 2007.

G. Viale, N. Rotmensz, P. Maisonneuve, L. Bottiglieri, E. Montagna et al., Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity, Breast Cancer Res Treat, vol.116, issue.2, pp.317-345, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00478271

M. L. Burness, T. A. Grushko, and O. I. Olopade, Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?, Cancer J, vol.16, issue.1, pp.23-32, 2010.

J. G. Klijn, P. M. Berns, P. I. Schmitz, and J. A. Foekens, The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients, Endocr Rev, vol.13, issue.1, pp.3-17, 1992.

F. Milanezi, S. Carvalho, and F. C. Schmitt, EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy, Expert Rev Mol Diagn, vol.8, issue.4, pp.417-451, 2008.

W. Jacot, E. Lopez-crapez, S. Thezenas, R. Senal, F. Fina et al., Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles, Breast Cancer Res, vol.13, issue.6, p.133, 2011.

R. Bhargava, W. L. Gerald, A. R. Li, Q. Pan, P. Lal et al., EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations, Mod Pathol, vol.18, issue.8, pp.1027-1060, 2005.

T. Toyama, H. Yamashita, N. Kondo, K. Okuda, S. Takahashi et al., Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers, BMC Cancer, vol.8, p.309, 2008.

H. Nakajima, Y. Ishikawa, M. Furuya, T. Sano, Y. Ohno et al., Protein expression, gene amplification, and mutational analysis of EGFR in triplenegative breast cancer. Breast Cancer, 2012.

V. Martin, F. Botta, E. Zanellato, F. Molinari, S. Crippa et al., Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features, Histol Histopathol, vol.27, issue.6, pp.785-92, 2012.

B. Gumuskaya, M. Alper, S. Hucumenoglu, K. Altundag, A. Uner et al., EGFR expression and gene copy number in triple-negative breast carcinoma, Cancer Genet Cytogenet, vol.203, issue.2, pp.222-231, 2010.

T. W. Miller, B. N. Rexer, J. T. Garrett, and C. L. Arteaga, Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer, Breast Cancer Res, vol.13, issue.6, p.224, 2011.

L. H. Saal, K. Holm, M. Maurer, L. Memeo, T. Su et al., PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma, Cancer Res, vol.65, issue.7, pp.2554-2563, 2005.

E. Lopez-knowles, O. 'toole, S. A. Mcneil, C. M. Millar, E. K. Qiu et al., PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality, Int J Cancer, vol.126, issue.5, pp.1121-1152, 2010.

K. Kalinsky, L. M. Jacks, A. Heguy, S. Patil, M. Drobnjak et al., PIK3CA mutation associates with improved outcome in breast cancer, Clin Cancer Res, vol.15, issue.16, pp.5049-59, 2009.

A. M. Gonzalez-angulo, J. Ferrer-lozano, K. Stemke-hale, A. Sahin, S. Liu et al., PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer, Mol Cancer Ther, vol.10, issue.6, pp.1093-101, 2011.

A. M. Gonzalez-angulo, K. Stemke-hale, S. L. Palla, M. Carey, R. Agarwal et al., Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer, Clin Cancer Res, vol.15, issue.7, pp.2472-2480, 2009.

P. J. Lamy, F. Fina, C. Bascoul-mollevi, A. C. Laberenne, P. M. Martin et al., Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers, Breast Cancer Res, vol.13, issue.1, p.15, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01825781

P. J. Lamy, N. I. Fina, F. Bibeau, F. , R. S. Dussert et al., Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer, Int J Biol Markers, vol.21, issue.1, pp.20-29, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01823855

A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann et al., Meeting highlights: international expert consensus on the primary therapy of early breast cancer, Ann Oncol, vol.16, issue.10, pp.1569-83, 2005.

W. Jacot, M. Gutowski, D. Azria, and G. Romieu, Adjuvant early breast cancer systemic therapies according to daily used technologies, Crit Rev Oncol Hematol, 2011.

P. J. Lamy, T. Verjat, A. C. Servanton, M. Paye, P. Leissner et al., Urokinasetype plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression, Am J Clin Pathol, vol.128, issue.3, pp.404-417, 2007.

M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo et al., Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant! St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial, Ann Oncol, vol.20, issue.2, pp.258-64, 2009.

V. Secq, J. Villeret, F. Fina, M. Carmassi, X. Carcopino et al., Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations, Br J Cancer, vol.110, issue.4, pp.1045-52, 2014.

E. Y. Cho, M. H. Chang, Y. L. Choi, J. E. Lee, S. J. Nam et al., Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC), Cancer Chemother Pharmacol, vol.68, issue.3, pp.753-61, 2011.

S. P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.486, issue.7403, pp.395-404, 2012.

H. S. Park, M. H. Jang, E. J. Kim, H. J. Kim, H. J. Lee et al., High EGFR gene copy number predicts poor outcome in triple-negative breast cancer, Mod Pathol, vol.27, issue.9, pp.1212-1234, 2014.

Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak et al., High frequency of mutations of the PIK3CA gene in human cancers, Science, vol.304, issue.5670, p.554, 2004.

R. Arsenic, A. Lehmann, J. Budczies, I. Koch, J. Prinzler et al., Analysis of PIK3CA mutations in breast cancer subtypes, Appl Immunohistochem Mol Morphol, vol.22, issue.1, pp.50-56, 2014.

K. Stemke-hale, A. M. Gonzalez-angulo, A. Lluch, R. M. Neve, W. L. Kuo et al., An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer, Cancer Res, vol.68, issue.15, pp.6084-91, 2008.

M. Cizkova, A. Susini, S. Vacher, G. Cizeron-clairac, C. Andrieu et al., PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups, Breast Cancer Res, vol.14, issue.1, p.28, 2012.

L. Zhao and P. K. Vogt, Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms, Proc Natl Acad Sci, vol.105, issue.7, pp.2652-2659, 2008.

Y. R. Liu, Y. Z. Jiang, W. J. Zuo, K. D. Yu, and Z. M. Shao, PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis, OncoTargets and therapy, vol.7, pp.543-52, 2014.

K. Hashimoto, H. Tsuda, F. Koizumi, C. Shimizu, K. Yonemori et al., Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer, Ann Oncol, vol.25, issue.10, pp.1973-1982, 2014.

S. Banerji, K. Cibulskis, C. Rangel-escareno, K. K. Brown, S. L. Carter et al., Sequence analysis of mutations and translocations across breast cancer subtypes, Nature, vol.486, issue.7403, pp.405-414, 2012.

M. Inanc, M. Ozkan, H. Karaca, V. Berk, O. Bozkurt et al., Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer, Med Oncol, vol.31, issue.1, p.801, 2014.

J. Iqbal, A. A. Thike, P. Y. Cheok, G. M. Tse, and P. H. Tan, Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer, Histopathology, vol.61, issue.4, pp.652-661, 2012.

R. A. Sanford, J. Song, A. M. Gutierrez-barrera, J. Profato, A. Woodson et al., High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors, Cancer, vol.121, pp.3422-3429, 2015.